by Madaline Spencer | Aug 28, 2025
Mario Maldonado, MD, Global Head of Clinical Development for Endocrinology at Recordati Rare Diseases, discusses Recordati’s presentations at ENDO 2025. LINC6 Clinical Trial LINC 6 is an ongoing, prospective observational study evaluating the long-term...
by Madaline Spencer | Aug 27, 2025
Alan Krasner, MD, Chief Endocrinologist at Crinetics Pharmaceuticals, discusses atumelnant for the treatment of patients with congenital adrenal hyperplasia (CAH). CAH is a genetic condition characterized by an enzyme deficiency in the adrenal glands....
by Madaline Spencer | Aug 26, 2025
Jason Crompton, PharmD, Global Medical Director of the Acromegaly Program at Chiesi Rare Diseases, discusses disparities between biochemical control and symptom burden in patients with acromegaly. Acromegaly is a hormonal disorder that results from the...
by Madaline Spencer | Aug 25, 2025
Mohamed Ladha, President and General Manager for Recordati Rare Diseases North America, discusses the company’s rare disease initiatives. The U.S. branch of Recordati was established in 2013 with a focus on products to treat patients with rare inherited...
by Madaline Spencer | Aug 22, 2025
The U.S. Food and Drug Administration has approved Dawnzera (donidalorsen) for prophylaxis treatment to prevent attacks in patients ages 12 years and older with hereditary angioedema (HAE). HAE is a genetic condition characterized by recurrent episodes of severe...
